Brief Report - (2025) Volume 9, Issue 6
Received: 02-Nov-2025, Manuscript No. hps-26-184505;
Editor assigned: 04-Nov-2025, Pre QC No. P-184505;
Reviewed: 18-Nov-2025, QC No. Q-184505;
Revised: 24-Nov-2025, Manuscript No. R-184505;
Published:
29-Nov-2025
, DOI: 10.37421/2573-4563.2025.9.372
Citation: Al-Khatib, Noura S.. ”Autophagy’s Dual Role in Pancreatic Diseases.” J Hepatol Pancreat Sci 09 (2025):372.
Copyright: © 2025 Al-Khatib S. Noura This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Autophagy, a fundamental cellular process involving the degradation and recycling of cellular components, exhibits a complex and often paradoxical role in the context of pancreatic diseases. In pancreatic cells, autophagy can act as a critical survival mechanism, particularly under conditions of cellular stress, helping to maintain homeostasis and cellular integrity. However, in the setting of chronic pancreatic conditions, this same process may inadvertently contribute to cell death, presenting a nuanced challenge for therapeutic intervention [1].
Selective autophagy, a more specific form of the process, has garnered significant attention for its involvement in the dysfunction of pancreatic beta-cells. Furthermore, alterations in selective autophagy are implicated in the pathogenesis of pancreatitis, suggesting that modulating these specific pathways could unlock novel therapeutic avenues for these conditions [2].
Aberrant autophagic activity is increasingly recognized as a key player in the development and progression of chronic pancreatitis. This dysregulation can lead to direct damage to acinar cells and trigger inflammatory responses within the pancreas. Consequently, targeting autophagy presents a potential strategy to mitigate the relentless progression of this debilitating disease [3].
Within the challenging landscape of pancreatic cancer, autophagy demonstrates a dualistic nature. On one hand, it can support the survival of tumor cells by supplying essential nutrients and clearing damaged organelles, thereby aiding tumor growth and resilience. On the other hand, it can render cancer cells more vulnerable to specific therapeutic agents, highlighting the critical importance of understanding its context-dependent functions [4].
In acute pancreatitis, the induction of autophagy has shown a remarkable protective effect on pancreatic acinar cells. Specifically, it appears to shield these vital cells from injury induced by agents like cerulein, a process largely mediated by the efficient removal of damaged mitochondria, a process known as mitophagy [5].
The intricate relationship between autophagy and endoplasmic reticulum (ER) stress is a critical determinant of pancreatic cell fate. When this balance is disrupted, particularly when ER stress-induced autophagy is dysregulated, it can significantly contribute to the demise of pancreatic cells, underscoring the importance of this cellular crosstalk [6].
Given its multifaceted role, the modulation of autophagy is actively being explored as a promising therapeutic strategy for pancreatic cancer. The goal is often to enhance the sensitivity of tumors to conventional chemotherapy or to directly induce cancer cell death. However, careful consideration of the timing and specific type of autophagic intervention is paramount for success [7].
Evidence suggests that an impairment in the autophagic flux, the complete process of autophagy from initiation to degradation, plays a significant role in the advancement of pancreatic ductal adenocarcinoma (PDAC). This impaired flux can bolster tumor cell survival and foster resistance to various therapeutic treatments, indicating that restoring autophagic function may be a beneficial approach [8].
The process of pancreatic beta-cell regeneration, crucial for maintaining glucose homeostasis, is another area where autophagy's role is under intense investigation. While autophagy can promote beta-cell survival during stressful periods, an overabundance or dysregulation of this process might hinder the intricate mechanisms required for effective regeneration [9].
Furthermore, specific autophagy-related genes (ATGs), which are essential components of the autophagic machinery, exhibit differential expression patterns in pancreatic cancer. This differential expression suggests their potential utility as biomarkers for prognosis and prediction, as well as targets for novel therapeutic interventions. Understanding these specific autophagic pathways is therefore key to unlocking their clinical potential [10].
Autophagy, a conserved cellular degradation pathway, plays a multifaceted role in pancreatic cell biology, influencing both survival and death under various physiological and pathological conditions. Its dual nature as a survival mechanism under stress, but a potential contributor to cell death in chronic states, necessitates a deep understanding for therapeutic development in pancreatic diseases [1].
The concept of selective autophagy, which targets specific cellular components for degradation, is particularly relevant to pancreatic beta-cell health and disease. Research indicates its crucial involvement in beta-cell dysfunction and the context of pancreatitis, suggesting that fine-tuning these selective pathways could offer targeted therapeutic benefits [2].
Chronic pancreatitis is significantly associated with aberrant autophagy, leading to a cascade of events including acinar cell damage and sustained inflammation. Therefore, interventions aimed at modulating autophagy are being investigated as a means to halt or slow down the progression of this chronic pancreatic condition [3].
In the context of pancreatic cancer, autophagy's contribution is complex, acting as a double-edged sword. It can facilitate tumor cell survival by providing essential nutrients through the breakdown of cellular components and clearing damaged organelles, yet it also creates vulnerabilities that can be exploited by specific therapeutic strategies [4].
The protective capabilities of autophagy have been demonstrated in acute pancreatitis, where its induction safeguards pancreatic acinar cells from cerulein-induced injury. This protective effect is largely attributed to the efficient clearance of damaged mitochondria through mitophagy, preventing cellular damage [5].
A critical interplay exists between autophagy and endoplasmic reticulum (ER) stress within pancreatic cells. The dysregulation of autophagy pathways that are activated by ER stress can lead to pancreatic cell demise, highlighting the sensitivity of these cells to disruptions in cellular stress response mechanisms [6].
Therapeutic strategies for pancreatic cancer are increasingly exploring the modulation of autophagy. The aim is to either sensitize tumor cells to existing chemotherapies or to directly induce cell death through autophagic mechanisms. However, the success of such interventions hinges on precise control over the timing and type of autophagic manipulation [7].
Studies have pointed towards impaired autophagy flux as a contributing factor to the progression of pancreatic ductal adenocarcinoma (PDAC). This cellular dysfunction promotes tumor cell survival and enhances resistance to therapies, suggesting that restoring the normal autophagic process could be a valuable therapeutic strategy [8].
Research into the role of autophagy in pancreatic beta-cell regeneration is ongoing, with potential implications for diabetes management. While autophagy can support beta-cell survival during stress, its excessive or dysregulated activity might impede the regenerative capacity of these critical cells [9].
Specific autophagy-related genes (ATGs) have emerged as key players in pancreatic cancer, exhibiting differential expression that could serve as prognostic and predictive biomarkers. Understanding the functions of these specific ATGs is essential for developing targeted therapies and improving patient outcomes [10].
Autophagy plays a dual role in pancreatic diseases, acting as a survival mechanism under stress but also potentially contributing to cell death in chronic conditions. Research highlights the importance of selective autophagy in pancreatic beta-cell dysfunction and pancreatitis, with modulation offering therapeutic avenues. Aberrant autophagy is implicated in chronic pancreatitis, leading to cell damage and inflammation, while in pancreatic cancer, it supports tumor survival but also creates vulnerabilities. Autophagy induction protects pancreatic acinar cells from injury in acute pancreatitis by clearing damaged mitochondria. The interplay between autophagy and ER stress is critical, with dysregulation leading to cell demise. Autophagy modulation is being explored as a therapeutic strategy for pancreatic cancer, aiming to enhance treatment efficacy. Impaired autophagy flux contributes to pancreatic ductal adenocarcinoma progression, suggesting restoration could be beneficial. Autophagy's role in pancreatic beta-cell regeneration is also under investigation. Specific autophagy-related genes show potential as biomarkers and therapeutic targets in pancreatic cancer.
None
None
Hepatology and Pancreatic Science received 34 citations as per Google Scholar report
